Suppr超能文献

核黄素与紫外线A作为棘阿米巴包囊的辅助治疗手段。

Riboflavin and ultraviolet A as adjuvant treatment against Acanthamoeba cysts.

作者信息

Lamy Ricardo, Chan Elliot, Good Samuel D, Cevallos Vicky, Porco Travis C, Stewart Jay M

机构信息

Department of Ophthalmology, University of California - San Francisco, San Francisco, California, USA.

Francis I. Proctor Foundation, University of California - San Francisco, San Francisco, California, USA.

出版信息

Clin Exp Ophthalmol. 2016 Apr;44(3):181-7. doi: 10.1111/ceo.12644. Epub 2016 Feb 23.

Abstract

BACKGROUND

Experimental studies have shown that the standard dose of riboflavin (R) or R + ultraviolet-A (UVA) as solo treatment are not able to exterminate Acanthamoeba cysts or even trophozoites. The purpose of this study is to determine whether the application of R + UVA can enhance the cysticidal effects of cationic antiseptic agents in vitro.

METHODS

The log of either polyhexamethylene biguanide or chlorhexidine minimal cysticidal concentration in solutions containing riboflavin (concentrations 0.1, 0.05 and 0.025%) plus either Acanthamoeba castellanii cysts or Acanthamoeba polyphaga cysts was determined and compared in groups treated with UVA 30 mW/cm(2) for 30 min and in control groups (with no exposure to UVA). A permutation test was used to determine the P value associated with treatment.

RESULTS

Regardless of the riboflavin concentration and UVA treatment condition, no trophozoites were seen in plates where the cysts were previously exposed to cationic antiseptic agent concentrations ≥200 µg/mL for Acanthamoeba castellanii samples and ≥100 µg/mL for A. polyphaga samples. There was no statistical evidence that R + UVA treatment was associated with minimal cysticidal concentration (P = 0.82).

CONCLUSION

R + UVA in doses up to 10 times higher than recommended for corneal crosslinking does not enhance the cysticidal effect of either polyhexamethylene biguanide or chlorhexidine in vitro.

摘要

背景

实验研究表明,标准剂量的核黄素(R)或R+紫外线A(UVA)单独治疗无法消灭棘阿米巴囊肿甚至滋养体。本研究的目的是确定R+UVA的应用是否能增强阳离子防腐剂在体外的杀囊肿作用。

方法

测定并比较在含有核黄素(浓度分别为0.1%、0.05%和0.025%)的溶液中,用30 mW/cm(2)的UVA照射30分钟的组和对照组(未暴露于UVA)中,聚六亚甲基双胍或氯己定对卡氏棘阿米巴囊肿或多食棘阿米巴囊肿的最低杀囊肿浓度对数。采用置换检验确定与治疗相关的P值。

结果

无论核黄素浓度和UVA处理条件如何,对于卡氏棘阿米巴样本,囊肿先前暴露于阳离子防腐剂浓度≥200 μg/mL,对于多食棘阿米巴样本,囊肿先前暴露于阳离子防腐剂浓度≥100 μg/mL的平板中均未见到滋养体。没有统计学证据表明R+UVA处理与最低杀囊肿浓度相关(P = 0.82)。

结论

剂量高达角膜交联推荐剂量10倍的R+UVA在体外不会增强聚六亚甲基双胍或氯己定的杀囊肿作用。

相似文献

1
Riboflavin and ultraviolet A as adjuvant treatment against Acanthamoeba cysts.
Clin Exp Ophthalmol. 2016 Apr;44(3):181-7. doi: 10.1111/ceo.12644. Epub 2016 Feb 23.
2
Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acanthamoeba isolates.
Am J Ophthalmol. 2012 Mar;153(3):399-404. doi: 10.1016/j.ajo.2011.07.025. Epub 2011 Oct 11.
4
Antimicrobial action of biguanides on the viability of Acanthamoeba cysts and assessment of cell toxicity.
Invest Ophthalmol Vis Sci. 2013 Sep 27;54(9):6363-72. doi: 10.1167/iovs.13-11990.
5
Effects of polyhexamethylene biguanide and chlorhexidine on four species of Acanthamoeba in vitro.
Curr Eye Res. 1996 Feb;15(2):225-8. doi: 10.3109/02713689608997418.
6
Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba castellanii.
Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):509-14. doi: 10.1007/s00417-012-2176-4. Epub 2012 Oct 19.
7
Phagocytosis affects biguanide sensitivity of Acanthamoeba spp.
Antimicrob Agents Chemother. 2002 Jul;46(7):2069-76. doi: 10.1128/AAC.46.7.2069-2076.2002.
8
Effect of Riboflavin/Rose Bengal-Mediated PACK-CXL on Acanthamoeba Trophozoites and Cysts in Vitro.
Curr Eye Res. 2018 Nov;43(11):1322-1325. doi: 10.1080/02713683.2018.1501074. Epub 2018 Aug 7.
9
10
Biguanide-induced changes in Acanthamoeba castellanii: an electron microscopic study.
J Appl Microbiol. 1998 Jan;84(1):53-62. doi: 10.1046/j.1365-2672.1997.00305.x.

引用本文的文献

1
Collagen cross-linking beyond corneal ectasia: A comprehensive review.
Indian J Ophthalmol. 2024 Feb 1;72(Suppl 2):S191-S202. doi: 10.4103/IJO.IJO_1507_23. Epub 2024 Jan 25.
2
antimicrobial efficacy of riboflavin, ultraviolet-A radiation, and combined riboflavin/ultraviolet-A radiation on ocular pathogens.
Taiwan J Ophthalmol. 2021 Aug 18;13(1):21-27. doi: 10.4103/tjo.tjo_28_21. eCollection 2023 Jan-Mar.
3
Use of corneal cross-linking beyond keratoconus: a systemic literature review.
Graefes Arch Clin Exp Ophthalmol. 2023 Sep;261(9):2435-2453. doi: 10.1007/s00417-023-05994-6. Epub 2023 Mar 7.
4
Treatment of recalcitrant Acanthamoeba Keratitis with Photoactivated Chromophore for Infectious Keratitis Corneal Collagen Cross-Linking (PACK-CXL).
Am J Ophthalmol Case Rep. 2022 Jan 22;25:101330. doi: 10.1016/j.ajoc.2022.101330. eCollection 2022 Mar.
6
Keratitis: an update on amebicidal and cysticidal drug screening methodologies and potential treatment with azole drugs.
Expert Rev Anti Infect Ther. 2021 Nov;19(11):1427-1441. doi: 10.1080/14787210.2021.1924673. Epub 2021 May 19.
7
High fluence PACK-CXL as adjuvant treatment for advanced Acanthamoeba keratitis.
Am J Ophthalmol Case Rep. 2019 Jun 20;15:100499. doi: 10.1016/j.ajoc.2019.100499. eCollection 2019 Sep.

本文引用的文献

1
Phylogenetic analysis and the evolution of the 18S rRNA gene typing system of Acanthamoeba.
J Eukaryot Microbiol. 2015 Jan-Feb;62(1):69-84. doi: 10.1111/jeu.12186.
2
Corneal cross linking and infectious keratitis: a systematic review with a meta-analysis of reported cases.
J Ophthalmic Inflamm Infect. 2013 May 29;3(1):47. doi: 10.1186/1869-5760-3-47.
3
Comparison of UVA- and UVA/riboflavin-induced growth inhibition of Acanthamoeba castellanii.
Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):509-14. doi: 10.1007/s00417-012-2176-4. Epub 2012 Oct 19.
4
Treatment of Acanthamoeba keratitis by corneal cross-linking.
Cornea. 2013 Feb;32(2):174-8. doi: 10.1097/ICO.0b013e31825cea99.
5
Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites.
Invest Ophthalmol Vis Sci. 2011 Dec 9;52(13):9333-8. doi: 10.1167/iovs.11-8382.
6
Practice patterns and opinions in the treatment of acanthamoeba keratitis.
Cornea. 2011 Dec;30(12):1363-8. doi: 10.1097/ICO.0b013e31820f7763.
7
Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acanthamoeba isolates.
Am J Ophthalmol. 2012 Mar;153(3):399-404. doi: 10.1016/j.ajo.2011.07.025. Epub 2011 Oct 11.
8
Microbiological cure times in acanthamoeba keratitis.
Eye (Lond). 2011 Sep;25(9):1155-60. doi: 10.1038/eye.2011.126. Epub 2011 Jun 3.
9
Corneal cross-linking and safety issues.
Open Ophthalmol J. 2011 Feb 11;5:14-6. doi: 10.2174/1874364101105010014.
10
Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases.
Ophthalmology. 2011 Feb;118(2):324-31. doi: 10.1016/j.ophtha.2010.06.041. Epub 2010 Sep 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验